drugset / Trial / NCT06942910

A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria

NCT06942910

Phase 2 Recruiting 224 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants with Chronic Kidney Disease and High Proteinuria

Timeline

Start
2025-05-07
Primary completion
2026-07-31
Completion
2026-07-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dapagliflozin Small molecule Oral
Subject Zibotentan Small molecule Oral